Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Leukemia ; 23(10): 1790-800, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19458627

ABSTRACT

Human umbilical cord blood (HUCB) provides a source of progenitors for cell therapy. We isolated and characterized an HUCB-derived population of progenitors (HUCBNP), differentiated toward neuronal phenotype by human neuroblastoma-conditioning medium (CM) and nerve growth factor (NGF), which have been found to confer neuroprotection toward hypoxia-mediated neuronal injury. This study investigated whether interferon-gamma (IFN-gamma) contributes to HUCBNP differentiation. IFN-gamma was detected in the CM used for the induction of differentiation of HUCBNP and a neutralizing antibody of IFN-gamma significantly inhibited either IFN-gamma or CM-induced differentiation. Transcriptome analysis of CM-differentiated HUCBNP, identified 86 genes as highly upregulated, among them 25 were IFN-induced (such as 2',5'-oligoadenylate synthetase 1 and 2, IFN-induced protein and transmembrane proteins, STAT1 (IFN-gamma-receptor signal transducer and activator of transcription) and chemokine C-X-C motif ligand 5). Treatment of HUCBNP with human recombinant IFN-gamma, inhibited cell proliferation in a dose-dependent manner. IFN-gamma (1-100 ng/ml) enhanced neuronal differentiation, expressed by neurite outgrowths and increased expression of the neuronal markers beta-tubulin III, microtubule-associated protein 2, neuronal nuclei, neurofilament M and neuronal-specific enolase. IFN-gamma additively cooperated with NGF to induce the differentiation of HUCBNP. These data indicate that IFN-gamma promotes neuronal differentiation of HUCB-derived progenitors, proposing its use in future protocols towards cell therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Differentiation/drug effects , Fetal Blood/drug effects , Interferon-gamma/pharmacology , Neurons/drug effects , Stem Cells/drug effects , 2',5'-Oligoadenylate Synthetase/genetics , 2',5'-Oligoadenylate Synthetase/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Cell Proliferation/drug effects , Cells, Cultured , Culture Media, Conditioned/pharmacology , Enzyme-Linked Immunosorbent Assay , Fetal Blood/cytology , Fetal Blood/metabolism , Gene Expression Profiling , Humans , Immunoenzyme Techniques , Neuroblastoma/drug therapy , Neuroblastoma/metabolism , Neuroblastoma/pathology , Neurons/cytology , Neurons/metabolism , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Proteins , Reverse Transcriptase Polymerase Chain Reaction , STAT1 Transcription Factor/genetics , STAT1 Transcription Factor/metabolism , Stem Cells/metabolism
2.
Endothelium ; 15(5-6): 288-98, 2008.
Article in English | MEDLINE | ID: mdl-19065320

ABSTRACT

Very few studies describe endothelial cell (EC) properties under three-dimensional (3D) conditions using (31)P magnetic resonance spectroscopy (MRS). The authors developed a model in which living ECs growing in Matrigel threads (3D conditions) for 5 days are monitored by (31)P MRS, providing the fingerprint of the major EC phosphometabolites. Organic extracts of membranal phospholipids were also analyzed by (31)P MRS. For comparison and as a model for two-dimensional (2D) tissue culture conditions, (31)P MRS spectra of aqueous extracts of EC phosphometabolites grown under 2D conditions were also evaluated. The phosphometabolites fingerprint of the cells cultured under 3D was significantly different from that of ECs maintained under 2D. Moreover, the pattern of phosphometabolites was affected by coculture with C6-glioma cells and upon treatment with valproic acid, which is under clinical investigation as an antioangiogenic anticancer drug. The major effects were modulation of (i) energy metabolism intermediates such as phosphocreatine, (ii) precursors of phospholipids such as phosphomonoesters, and (iii) degradation products of phospholipids such as glycerophosphocholine. This endothelial model will be usefull as an enabling platform technology for tissue engineering.


Subject(s)
Bioreactors , Endothelial Cells/metabolism , Magnetic Resonance Spectroscopy/methods , Neuroglia/metabolism , Phospholipids/metabolism , Valproic Acid/pharmacology , Animals , Anticonvulsants/pharmacology , Biochemistry/methods , Biological Assay/instrumentation , Biological Assay/methods , Cell Communication/physiology , Cell Line , Cell Line, Tumor , Coculture Techniques , Collagen/pharmacology , Drug Combinations , Endothelial Cells/drug effects , Energy Metabolism/drug effects , Energy Metabolism/physiology , Laminin/pharmacology , Lipid Metabolism/drug effects , Organ Culture Techniques/methods , Phosphocreatine/metabolism , Phosphorus Isotopes/chemistry , Proteoglycans/pharmacology , Rats
3.
Endothelium ; 15(5-6): 299-307, 2008.
Article in English | MEDLINE | ID: mdl-19065321

ABSTRACT

In the accompanying study, the authors presented phosphometabolite patterns of endothelial cells grown under three-dimensional (3D) conditions using (31)P magnetic resonance spectroscopy (MRS). Here the authors describe the effect of nonsteroidal anti-inflammatory drugs (NSAIDs), using this enabling platform technology, which is relevant for evaluating drug effects in tissue-engineered endothelial constructs. Treatment with indomethacin significantly changed the phosphometabolite fingerprint in this endothelial model, by, respectively, increasing (81%) and decreasing (42%) glycerophosphocholine (GPC) and phosphomonoesters (PM). Furthermore, a safer approach using a NSAID prodrug was also demonstrated in this study with a indomethacin phospholipid-derived prodrug (DP-155). Like the parental drug, DP-155 increased and decreased the levels of GPC and PM by 100% and 20%, respectively. These changes represent useful biomarkers to monitor NSAID effects on endothelized tissue-engineered constructs for the purpose of controlling endothelial cell survival and inflammation upon implantation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Bioreactors , Endothelial Cells/metabolism , Magnetic Resonance Spectroscopy/methods , Neuroglia/metabolism , Phospholipids/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Biochemistry/methods , Biological Assay/instrumentation , Biological Assay/methods , Cell Communication/physiology , Cell Line , Cell Line, Tumor , Coculture Techniques , Collagen/pharmacology , Drug Combinations , Endothelial Cells/drug effects , Indomethacin/analogs & derivatives , Indomethacin/pharmacology , Inflammation/drug therapy , Laminin/pharmacology , Lipid Metabolism/drug effects , Organ Culture Techniques/methods , Phosphatidylcholines/pharmacology , Phosphorus Isotopes/chemistry , Proteoglycans/pharmacology , Rats
4.
Kidney Int ; 74(1): 91-100, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18385664

ABSTRACT

Plasma endothelin-1 levels rise in diabetes and after exposure to contrast media suggesting a role in progressive diabetic and acute radiocontrast nephropathies. Here we studied individual and combined effects of streptozotocin-induced diabetes and contrast media on renal endothelin converting enzyme-1 levels in the rat. In vivo, medullary (but not cortical) endothelin converting enzyme protein gradually increased 4 to 5-fold following the induction of diabetes or after the administration of contrast media but rose 15-fold when diabetic rats were given contrast media. Changes in mRNA expression paralleled those of the protein. Immunohistochemistry confirmed that increased tubular and endothelial cell endothelin converting enzyme-1 were most pronounced in the medulla. In vitro, endothelin-1 levels increased 3-fold following incubation of endothelial cells with media high in glucose or with contrast and 4-fold with their combination. Endothelin converting enzyme-1 protein and mRNA expression changed in a similar pattern while prepro endothelin-1 mRNA increased with each insult but not in an additive way. Our study shows that diabetes and contrast media up-regulate renal medullary endothelin converting enzyme-1 expression and synthesis.


Subject(s)
Aspartic Acid Endopeptidases/analysis , Contrast Media/adverse effects , Diabetes Mellitus, Experimental/enzymology , Diabetic Nephropathies/etiology , Kidney/enzymology , Metalloendopeptidases/analysis , Animals , Aspartic Acid Endopeptidases/genetics , Diabetes Mellitus, Experimental/complications , Endothelin-1/analysis , Endothelin-Converting Enzymes , Metalloendopeptidases/genetics , RNA, Messenger/analysis , Rats , Up-Regulation
5.
Schizophr Res ; 52(1-2): 121-6, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11595399

ABSTRACT

The phospholipid composition of red blood cells (RBC) from 32 haloperidol-treated schizophrenic patients, classified according to the positive and negative syndrome scale (PANSS) as showing either predominantly positive or predominantly negative symptoms, was determined and compared with that of normal controls. While the levels of phosphatidylcholine and phosphatidylserine were similar in all three groups, sphingomyelin (SM) and phosphatidylethanolamine (PE) were, respectively, increased and decreased in RBCs of schizophrenic patients. In both patient groups, the SM/PE ratios correlated directly with the PANSS negative symptom scale scores and inversely with the positive symptom scale scores. However, the inverse changes in the contents of SM and PE were much more expressed in the negative group. It is suggested that a main source of that difference is a higher activity of the polyunsaturated acid-selective phospholipase A(2) in the negative syndrome patients than in the positive syndrome and control groups.


Subject(s)
Erythrocytes/metabolism , Phospholipids/blood , Schizophrenia/blood , Schizophrenic Psychology , Adult , Depression/blood , Depression/diagnosis , Depression/psychology , Female , Hallucinations/blood , Hallucinations/diagnosis , Hallucinations/psychology , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Reference Values , Schizophrenia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL